HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Chronic theatment with an endothelin-converting enzyme inhibitor reduces the development of hypoxia-induced pulmonary hypertension in rat].

Abstract
The aim of this study was to investigate how blocking functional endothelin-converting enzyme activity may offer a new approach to inhibition of changes in pulmonary vessels reactivity due to development of hypoxia-induced pulmonary arterial hypertension in rats. This data shows that treatment with endothelin-converting enzyme blocker PP36 significantly reduced pathological changes due to hypoxia-induced pulmonary hypertension. One of the reasons may be the increased production and role of nitric oxide in pulmonary artery tone.
AuthorsA I Simonova, V F Pozdneev, O A Gomazkov, N A Medvedeva
JournalRossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova (Ross Fiziol Zh Im I M Sechenova) Vol. 94 Issue 7 Pg. 777-84 (Jul 2008) ISSN: 0869-8139 [Print] Russia (Federation)
PMID18767389 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dipeptides
  • Endothelin-1
  • Nitric Oxide Donors
  • Propanolamines
  • Succinates
  • 5'-((N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)glycyl)amino)-5'-deoxyuridine
  • Nitric Oxide Synthase
  • Aspartic Acid Endopeptidases
  • Metalloendopeptidases
  • Endothelin-Converting Enzymes
  • Deoxyuridine
Topics
  • Animals
  • Aspartic Acid Endopeptidases (antagonists & inhibitors)
  • Blood Circulation
  • Deoxyuridine (analogs & derivatives)
  • Dipeptides (administration & dosage, therapeutic use)
  • Endothelin-1 (blood)
  • Endothelin-Converting Enzymes
  • Hypertension, Pulmonary (etiology, physiopathology, prevention & control)
  • Hypoxia (complications)
  • Injections, Intravenous
  • Male
  • Metalloendopeptidases (antagonists & inhibitors)
  • Nitric Oxide Donors (pharmacology)
  • Nitric Oxide Synthase (antagonists & inhibitors)
  • Propanolamines
  • Rats
  • Rats, Wistar
  • Succinates (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: